论文部分内容阅读
目的:检测CREPT(cell-cycle related and expression-elevated protein in tumor)与细胞周期蛋白D(CyclinD3)在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达,分析二者在促进NSCLC发生发展过程中的作用。方法:免疫组织化学法检测CREPT、CyclinD3在271例NSCLC及相应正常组织中的表达情况,统计学分析二者间的相关性及其在临床病理因素中的差异性。结果:CREPT和CyclinD3定位于细胞核与细胞质中,在NSCLC组织中高表达,癌组织与正常组织中阳性表达率差异性极显著(P<0.001)。CREPT、CyclinD3在腺癌、鳞癌间表达无统计学差异(P=0.638,P=0.503);在总NSCLC、腺癌、鳞癌的病理分级间,表达均具有极显著性差异(P<0.001);在总NSCLC组织TNM分期、淋巴结是否转移间的表达差异性显著(P=0.025,P=0.001;P=0.003,P=0.026);在总NSCLC、腺癌、鳞癌中,CREPT和CyclinD3表达秩相关系数r分别是0.458、0.393、0.468;P<0.001,二者具有正相关性。结论:CREPT和CyclinD3是NSCLC组织与相应正常组织表达的差异蛋白,二者的过表达可能在NSCLC的发生发展过程中起作用。
Objective: To detect the expression of CREPT and CyclinD3 in non-small cell lung cancer (NSCLC) The role of the development process. Methods: The expressions of CREPT and CyclinD3 in 271 cases of NSCLC and its corresponding normal tissues were detected by immunohistochemistry. The correlation between them and their differences in clinicopathological factors were statistically analyzed. Results: The expressions of CREPT and CyclinD3 in nucleus and cytoplasm were highly expressed in NSCLC tissues. The positive rates of expression of CREPT and CyclinD3 were significantly different between normal tissues and cancerous tissues (P <0.001). The expression of CREPT and CyclinD3 was not significantly different between adenocarcinoma and squamous cell carcinoma (P = 0.638, P = 0.503). The expression of CREPT and CyclinD3 was significantly different between the NSCLC, adenocarcinoma and squamous cell carcinoma ); The expression of CRET and CyclinD3 in all NSCLC, adenocarcinoma and squamous cell carcinoma was significantly different between TNM staging and lymph node metastasis (P = 0.025, P = 0.001; P = 0.003) The rank correlation coefficients r were 0.458,0.393,0.468 respectively; P <0.001, the two had a positive correlation. CONCLUSIONS: CREPT and CyclinD3 are differentially expressed proteins in NSCLC tissues and corresponding normal tissues. The overexpression of both may play a role in the genesis and development of NSCLC.